Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZVS106e in ABCA4-mutated Hereditary Retinal Degeneration (Stargardt Disease)
NCT07241169Phase 1Recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Dec 2025
- Primary completion
- Nov 2028
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZVS106e in Stargardt disease (STGD), sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Safety and tolerability of subretinal injection of ZVS106e solution at 52 weeks. Started Dec 2025; status: recruiting.
02
Drugs
ZVS106e
03
Conditions
Stargardt disease (STGD)
Beyond the preview
Go deeper on NCT07241169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241169.